These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12573320)

  • 1. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
    Ben-David I; Rozen Y; Ortu G; Mishani E
    Appl Radiat Isot; 2003 Feb; 58(2):209-17. PubMed ID: 12573320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
    Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
    Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
    Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
    Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
    Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
    J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
    Gao M; Lola CM; Wang M; Miller KD; Sledge GW; Zheng QH
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3222-6. PubMed ID: 21549594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
    Hirata M; Kanai Y; Naka S; Yoshimoto M; Kagawa S; Matsumuro K; Katsuma H; Yamaguchi H; Magata Y; Ohmomo Y
    Ann Nucl Med; 2013 Jun; 27(5):431-43. PubMed ID: 23494210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
    Bonasera TA; Ortu G; Rozen Y; Krais R; Freedman NM; Chisin R; Gazit A; Levitzki A; Mishani E
    Nucl Med Biol; 2001 May; 28(4):359-74. PubMed ID: 11395308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
    VanBrocklin HF; Lim JK; Coffing SL; Hom DL; Negash K; Ono MY; Gilmore JL; Bryant I; Riese DJ
    J Med Chem; 2005 Nov; 48(23):7445-56. PubMed ID: 16279804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.
    Fredriksson A; Johnström P; Thorell JO; von Heijne G; Hassan M; Eksborg S; Kogner P; Borgström P; Ingvar M; Stone-Elander S
    Life Sci; 1999; 65(2):165-74. PubMed ID: 10416822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
    Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
    Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.
    Dissoki S; Aviv Y; Laky D; Abourbeh G; Levitzki A; Mishani E
    Appl Radiat Isot; 2007 Oct; 65(10):1140-51. PubMed ID: 17574425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-aminoquinazoline analogs: a novel class of anticancer agents.
    Singh K; Sharma PP; Kumar A; Chaudhary A; Roy RK
    Mini Rev Med Chem; 2013 Jun; 13(8):1177-94. PubMed ID: 22697512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
    Wang JQ; Gao M; Miller KD; Sledge GW; Zheng QH
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4102-6. PubMed ID: 16697188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
    Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
    Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
    Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
    Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
    J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase.
    Lee JY; Park YK; Seo SH; So IS; Chung HK; Yang BS; Lee SJ; Park H; Lee YS
    Arch Pharm (Weinheim); 2001 Nov; 334(11):357-60. PubMed ID: 11822173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.